WO2007110152A2 - Polylactid-nanopartikel - Google Patents
Polylactid-nanopartikel Download PDFInfo
- Publication number
- WO2007110152A2 WO2007110152A2 PCT/EP2007/002198 EP2007002198W WO2007110152A2 WO 2007110152 A2 WO2007110152 A2 WO 2007110152A2 EP 2007002198 W EP2007002198 W EP 2007002198W WO 2007110152 A2 WO2007110152 A2 WO 2007110152A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agents
- nanoparticles
- lactide
- agent
- primary emulsion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- C08G63/08—Lactones or lactides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/225,555 US8003128B2 (en) | 2006-03-24 | 2007-03-13 | Polylactide nanoparticles |
NZ571354A NZ571354A (en) | 2006-03-24 | 2007-03-13 | Polylactide nanoparticles |
AU2007229738A AU2007229738A1 (en) | 2006-03-24 | 2007-03-13 | Polylactide nanoparticles |
EP07711937A EP1998752A2 (de) | 2006-03-24 | 2007-03-13 | Polylactid-nanopartikel |
BRPI0709352-7A BRPI0709352A2 (pt) | 2006-03-24 | 2007-03-13 | método para preparar um sistema de direcionamanto de droga, sistema de direcionamento de droga, método para o tratamento de um doença ou de uma desordem do sistema nevorso central de um mamìfero e uso do sistema de direcionamento de droga |
CA002644411A CA2644411A1 (en) | 2006-03-24 | 2007-03-13 | Polylactide nanoparticles |
MX2008011892A MX2008011892A (es) | 2006-03-24 | 2007-03-13 | Nanoparticulas de polilactido. |
JP2009500737A JP2009530325A (ja) | 2006-03-24 | 2007-03-13 | ポリラクチドナノ粒子 |
US13/136,015 US20110293730A1 (en) | 2006-03-24 | 2011-07-20 | Polylactide nanoparticles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006013531.8 | 2006-03-24 | ||
DE102006013531A DE102006013531A1 (de) | 2006-03-24 | 2006-03-24 | Polylactid-Nanopartikel |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/136,015 Division US20110293730A1 (en) | 2006-03-24 | 2011-07-20 | Polylactide nanoparticles |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007110152A2 true WO2007110152A2 (de) | 2007-10-04 |
WO2007110152A8 WO2007110152A8 (de) | 2007-12-13 |
WO2007110152A3 WO2007110152A3 (de) | 2008-02-21 |
Family
ID=38110479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/002198 WO2007110152A2 (de) | 2006-03-24 | 2007-03-13 | Polylactid-nanopartikel |
Country Status (14)
Country | Link |
---|---|
US (2) | US8003128B2 (de) |
EP (1) | EP1998752A2 (de) |
JP (1) | JP2009530325A (de) |
KR (1) | KR20080111079A (de) |
CN (1) | CN101410099A (de) |
AU (1) | AU2007229738A1 (de) |
BR (1) | BRPI0709352A2 (de) |
CA (1) | CA2644411A1 (de) |
DE (1) | DE102006013531A1 (de) |
IN (1) | IN2008DE08036A (de) |
MX (1) | MX2008011892A (de) |
NZ (1) | NZ571354A (de) |
RU (1) | RU2423104C2 (de) |
WO (1) | WO2007110152A2 (de) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010005344A1 (ru) * | 2008-07-09 | 2010-01-14 | Общество С Ограниченной Ответственностью "Akba-Aльяhc" | Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты) |
JP2011520802A (ja) * | 2008-05-06 | 2011-07-21 | グラクソ グループ リミテッド | 生物活性薬の封入 |
US8206747B2 (en) | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8518963B2 (en) | 2009-12-15 | 2013-08-27 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
CN103893769A (zh) * | 2014-04-16 | 2014-07-02 | 江西科技师范大学 | 含聚乙丙交酯靶向高分子药物载体及其制备方法 |
US9198874B2 (en) | 2008-12-15 | 2015-12-01 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
US9351933B2 (en) | 2008-06-16 | 2016-05-31 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
CN108395543A (zh) * | 2018-05-31 | 2018-08-14 | 华南理工大学 | 一种改性聚轮烷、基于聚轮烷的载药胶束及其制备方法与应用 |
US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
EP3750523A1 (de) * | 2019-06-13 | 2020-12-16 | CAPNOMED GmbH | System zur abgabe eines wirkstoffes |
EP3750524A1 (de) * | 2019-06-13 | 2020-12-16 | CAPNOMED GmbH | Verzögerte und anhaltende abgabe von antikrebsmitteln |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8946200B2 (en) * | 2006-11-02 | 2015-02-03 | Southwest Research Institute | Pharmaceutically active nanosuspensions |
US8404850B2 (en) * | 2008-03-13 | 2013-03-26 | Southwest Research Institute | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors |
US8722706B2 (en) * | 2008-08-15 | 2014-05-13 | Southwest Research Institute | Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts |
US8309134B2 (en) * | 2008-10-03 | 2012-11-13 | Southwest Research Institute | Modified calcium phosphate nanoparticle formation |
US9028873B2 (en) * | 2010-02-08 | 2015-05-12 | Southwest Research Institute | Nanoparticles for drug delivery to the central nervous system |
US8974691B2 (en) | 2010-09-24 | 2015-03-10 | Fujimi Incorporated | Composition for polishing and composition for rinsing |
JP5687354B2 (ja) * | 2010-11-26 | 2015-03-18 | ユニバーシティ・オブ・ザ・ウィットウォータースランド・ヨハネスブルグUniversity Of The Witwatersrand, Johannesburg | 薬物送達デバイス |
WO2012135010A2 (en) * | 2011-03-25 | 2012-10-04 | Selecta Biosciences, Inc. | Osmotic mediated release synthetic nanocarriers |
GB201209517D0 (en) * | 2012-05-29 | 2012-07-11 | Univ Birmingham | Nanoparticles |
ES2656091T3 (es) * | 2012-07-27 | 2018-02-23 | Izumi Technology, Llc. | Composiciones de inhibidores de eflujo y métodos de tratamiento que las utilizan |
RS58928B1 (sr) * | 2012-08-29 | 2019-08-30 | Hoffmann La Roche | Transporter za krvno-moždanu barijeru |
CL2012003209A1 (es) * | 2012-11-16 | 2013-04-19 | Univ Santiago Chile | Metodo de sintesis de nanoparticulas de acido poli (lactico-glicolico) (plga) con pentoxifilina; composicion farmaceutica que comprende nanoparticulas de plga con pentoxifilina; y uso de las nanoparticulas de plga cargada con pentoxifilina en el tratamiento del alivio y prevencion del dolor cronico. |
CN109613177B (zh) * | 2014-07-01 | 2021-08-20 | 科蒙森斯公司 | 用于鉴定羊水的诊断组合物 |
US10758520B1 (en) | 2015-05-20 | 2020-09-01 | University Of South Florida | Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier |
RU2595859C1 (ru) * | 2015-07-20 | 2016-08-27 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Полимеросодержащее лекарственное средство на основе противоопухолевого препарата этопозида |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
RU2606839C1 (ru) * | 2015-10-26 | 2017-01-10 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Лекарственный препарат противотуберкулезного действия на основе D-циклосерина в виде лиофилизата и способ получения лекарственного препарата |
RU2649743C1 (ru) * | 2016-10-24 | 2018-04-04 | Станислав Анатольевич Кедик | Жидкая лекарственная форма, содержащая лекарственное вещество, помещенное в биоразлагаемые полимеры |
CN106806352B (zh) * | 2017-01-26 | 2019-01-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种可缓释、靶向应用于神经退行性疾病的纳米药物 |
WO2018237004A1 (en) * | 2017-06-20 | 2018-12-27 | University Of Maryland, Baltimore | RARY LIGAND CHARGED SELECTIVE NANOPARTICLES FOR HANDLING TARGET BONE GROWTH |
RU2675810C1 (ru) * | 2017-12-19 | 2018-12-25 | Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" | Полимерный комплекс для молекулярно-прицельной терапии и способ его получения |
US10842755B2 (en) | 2018-03-23 | 2020-11-24 | University Of South Carolina | Nanoparticles for brain targeted drug delivery |
US20220175687A1 (en) * | 2019-04-11 | 2022-06-09 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
RU2734710C1 (ru) * | 2019-06-14 | 2020-10-22 | Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБТМ ФМБА России) | Наночастицы на основе биодеградирующих полимеров с инкапсулированными в них противоопухолевыми препаратами |
CN111939151A (zh) * | 2020-07-04 | 2020-11-17 | 浙江工业大学 | 一种复合型阿霉素白蛋白纳米粒及其制备方法和应用 |
CN116018401A (zh) * | 2020-07-29 | 2023-04-25 | 加利福尼亚大学董事会 | 驱动生肌性干细胞扩增的化学物混合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117454A (en) * | 1994-02-28 | 2000-09-12 | Medinova Medical Consulting Gmbh | Drug targeting to the nervous system by nanoparticles |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
WO2004084871A1 (en) * | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targenting drug delivery and sustained drug release |
WO2004112695A2 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llc | Methods and compositions for delivery of catecholic butanes for treatment of obesity |
EP1795185A2 (de) * | 2005-12-07 | 2007-06-13 | Cordis Corporation | Nano- und/oder Mikropartikelformulationen zur Behandlung von Gefäßerkrankungen auf der Basis lokaler Injektionen |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0725689B2 (ja) * | 1986-10-07 | 1995-03-22 | 中外製薬株式会社 | 顆粒球コロニ−刺激因子を含有する徐放性製剤 |
WO1998056361A1 (en) | 1997-06-13 | 1998-12-17 | Medinova Medical Consulting Gmbh | Drug targeting system, method of its preparation and its use |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20060024248A1 (en) * | 2003-03-23 | 2006-02-02 | Combe Incorporated | Composition and method employing membrane structured solid nanoparticles for enhanced delivery of oral care actives |
WO2005003180A2 (en) * | 2003-04-10 | 2005-01-13 | Pr Pharmaceuticals | A method for the production of emulsion-based micro particles |
US7728036B2 (en) * | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
US20050084456A1 (en) * | 2003-10-21 | 2005-04-21 | Liping Tang | Functionalized particles |
KR101123520B1 (ko) * | 2003-12-04 | 2012-03-13 | 디에스엠 아이피 어셋츠 비.브이. | 자외선 필터 활성을 갖는 미세캡슐 및 그의 제조방법 |
-
2006
- 2006-03-24 DE DE102006013531A patent/DE102006013531A1/de not_active Withdrawn
-
2007
- 2007-03-13 CA CA002644411A patent/CA2644411A1/en not_active Abandoned
- 2007-03-13 NZ NZ571354A patent/NZ571354A/en not_active IP Right Cessation
- 2007-03-13 MX MX2008011892A patent/MX2008011892A/es not_active Application Discontinuation
- 2007-03-13 AU AU2007229738A patent/AU2007229738A1/en not_active Abandoned
- 2007-03-13 WO PCT/EP2007/002198 patent/WO2007110152A2/de active Application Filing
- 2007-03-13 RU RU2008140367/15A patent/RU2423104C2/ru active IP Right Revival
- 2007-03-13 CN CNA2007800106413A patent/CN101410099A/zh active Pending
- 2007-03-13 JP JP2009500737A patent/JP2009530325A/ja active Pending
- 2007-03-13 KR KR1020087025603A patent/KR20080111079A/ko not_active Application Discontinuation
- 2007-03-13 US US12/225,555 patent/US8003128B2/en not_active Expired - Fee Related
- 2007-03-13 BR BRPI0709352-7A patent/BRPI0709352A2/pt not_active IP Right Cessation
- 2007-03-13 EP EP07711937A patent/EP1998752A2/de not_active Withdrawn
-
2008
- 2008-09-24 IN IN8036DE2008 patent/IN2008DE08036A/en unknown
-
2011
- 2011-07-20 US US13/136,015 patent/US20110293730A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117454A (en) * | 1994-02-28 | 2000-09-12 | Medinova Medical Consulting Gmbh | Drug targeting to the nervous system by nanoparticles |
US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
WO2004084871A1 (en) * | 2003-03-26 | 2004-10-07 | Ltt Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targenting drug delivery and sustained drug release |
WO2004112695A2 (en) * | 2003-05-20 | 2004-12-29 | Erimos Pharmaceutical Llc | Methods and compositions for delivery of catecholic butanes for treatment of obesity |
EP1795185A2 (de) * | 2005-12-07 | 2007-06-13 | Cordis Corporation | Nano- und/oder Mikropartikelformulationen zur Behandlung von Gefäßerkrankungen auf der Basis lokaler Injektionen |
Non-Patent Citations (9)
Title |
---|
DINTAMAN JAY M ET AL: "Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS)" PHARMACEUTICAL RESEARCH (NEW YORK), Bd. 16, Nr. 10, Oktober 1999 (1999-10), Seiten 1550-1556, XP002437572 ISSN: 0724-8741 * |
FENG S-S ET AL: "Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases" CHEMICAL ENGINEERING SCIENCE, OXFORD, GB, Bd. 58, Nr. 18, September 2003 (2003-09), Seiten 4087-4114, XP004453411 ISSN: 0009-2509 * |
MU ET AL: "Application of TPGS in polymeric nanoparticulate drug delivery system" COLLOIDS AND SURFACES. B, BIOINTERFACES, ELSEVIER, AMSTERDAM,, NL, Bd. 47, Nr. 1, 15. Januar 2006 (2006-01-15), Seiten 90-97, XP005251979 ISSN: 0927-7765 * |
MU L ET AL: "Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol<(>R))" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, Bd. 80, Nr. 1-3, 23. April 2002 (2002-04-23), Seiten 129-144, XP004348630 ISSN: 0168-3659 * |
MUELLER R H ET AL: "Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908" INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), Bd. 89, Nr. 1, 1993, Seiten 25-31, XP002456391 ISSN: 0378-5173 * |
REDHEAD H M ET AL: "Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation" JOURNAL OF CONTROLLED RELEASE, Bd. 70, Nr. 3, 23. Februar 2001 (2001-02-23), Seiten 353-363, XP002456390 ISSN: 0168-3659 * |
RUAN G ET AL: "Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, Bd. 84, Nr. 3, 5. Dezember 2002 (2002-12-05), Seiten 151-160, XP004395986 ISSN: 0168-3659 * |
YOON JEONG PARK ET AL: "SURFACE-MODIFIED POLY(LACTIDE-CO-GLYCOLIDE) NANOSPHERES FOR TARGETED BONE IMAGING WITH ENHANCED LABELING AND DELIVERY OF RADIOISOTOPE" JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, WILEY, NEW YORK, NY, US, Bd. 67A, Nr. 3, 2003, Seiten 751-760, XP008039693 ISSN: 0021-9304 * |
ZHANG ET AL: "Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, Bd. 27, Nr. 2, Januar 2006 (2006-01), Seiten 262-270, XP005071172 ISSN: 0142-9612 * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011520802A (ja) * | 2008-05-06 | 2011-07-21 | グラクソ グループ リミテッド | 生物活性薬の封入 |
US9579386B2 (en) | 2008-06-16 | 2017-02-28 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
EA021422B1 (ru) * | 2008-06-16 | 2015-06-30 | Бинд Терапьютикс, Инк. | Полимерные наночастицы, содержащие терапевтическое средство, и способ их получения |
US8318208B1 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9351933B2 (en) | 2008-06-16 | 2016-05-31 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
US8420123B2 (en) | 2008-06-16 | 2013-04-16 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8206747B2 (en) | 2008-06-16 | 2012-06-26 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9375481B2 (en) | 2008-06-16 | 2016-06-28 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8603534B2 (en) | 2008-06-16 | 2013-12-10 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9393310B2 (en) | 2008-06-16 | 2016-07-19 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8609142B2 (en) | 2008-06-16 | 2013-12-17 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8613954B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
US8617608B2 (en) | 2008-06-16 | 2013-12-31 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8623417B1 (en) | 2008-06-16 | 2014-01-07 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same |
US9579284B2 (en) | 2008-06-16 | 2017-02-28 | Pfizer Inc. | Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same |
US8652528B2 (en) | 2008-06-16 | 2014-02-18 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8663700B2 (en) | 2008-06-16 | 2014-03-04 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
WO2010005344A1 (ru) * | 2008-07-09 | 2010-01-14 | Общество С Ограниченной Ответственностью "Akba-Aльяhc" | Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты) |
US8905997B2 (en) | 2008-12-12 | 2014-12-09 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US9198874B2 (en) | 2008-12-15 | 2015-12-01 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
US9308179B2 (en) | 2008-12-15 | 2016-04-12 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
US9872848B2 (en) | 2009-12-11 | 2018-01-23 | Pfizer Inc. | Stable formulations for lyophilizing therapeutic particles |
US9498443B2 (en) | 2009-12-11 | 2016-11-22 | Pfizer Inc. | Stable formulations for lyophilizing therapeutic particles |
US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8603535B2 (en) | 2009-12-11 | 2013-12-10 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8956657B2 (en) | 2009-12-11 | 2015-02-17 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8916203B2 (en) | 2009-12-11 | 2014-12-23 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8637083B2 (en) | 2009-12-11 | 2014-01-28 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US9835572B2 (en) | 2009-12-15 | 2017-12-05 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US8912212B2 (en) | 2009-12-15 | 2014-12-16 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US8518963B2 (en) | 2009-12-15 | 2013-08-27 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US10555911B2 (en) | 2012-05-04 | 2020-02-11 | Yale University | Highly penetrative nanocarriers for treatment of CNS disease |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
US10071100B2 (en) | 2014-03-14 | 2018-09-11 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
CN103893769A (zh) * | 2014-04-16 | 2014-07-02 | 江西科技师范大学 | 含聚乙丙交酯靶向高分子药物载体及其制备方法 |
CN103893769B (zh) * | 2014-04-16 | 2016-03-23 | 江西科技师范大学 | 含聚乙丙交酯靶向高分子药物载体及其制备方法 |
US11584793B2 (en) | 2015-06-24 | 2023-02-21 | Hoffmann-La Roche Inc. | Anti-transferrin receptor antibodies with tailored affinity |
US11603411B2 (en) | 2015-10-02 | 2023-03-14 | Hoffmann-La Roche Inc. | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
CN108395543A (zh) * | 2018-05-31 | 2018-08-14 | 华南理工大学 | 一种改性聚轮烷、基于聚轮烷的载药胶束及其制备方法与应用 |
EP3750523A1 (de) * | 2019-06-13 | 2020-12-16 | CAPNOMED GmbH | System zur abgabe eines wirkstoffes |
EP3750524A1 (de) * | 2019-06-13 | 2020-12-16 | CAPNOMED GmbH | Verzögerte und anhaltende abgabe von antikrebsmitteln |
WO2020249384A1 (en) * | 2019-06-13 | 2020-12-17 | CAPNOMED GmbH | Delayed and sustained delivery of anticancer drugs |
WO2020249383A1 (en) * | 2019-06-13 | 2020-12-17 | CAPNOMED GmbH | Active substance delivery system |
Also Published As
Publication number | Publication date |
---|---|
EP1998752A2 (de) | 2008-12-10 |
US20110293730A1 (en) | 2011-12-01 |
WO2007110152A8 (de) | 2007-12-13 |
US8003128B2 (en) | 2011-08-23 |
IN2008DE08036A (de) | 2009-03-20 |
RU2423104C2 (ru) | 2011-07-10 |
DE102006013531A1 (de) | 2007-09-27 |
US20090263491A1 (en) | 2009-10-22 |
AU2007229738A1 (en) | 2007-10-04 |
KR20080111079A (ko) | 2008-12-22 |
MX2008011892A (es) | 2008-11-14 |
WO2007110152A3 (de) | 2008-02-21 |
BRPI0709352A2 (pt) | 2011-07-12 |
CA2644411A1 (en) | 2007-10-04 |
CN101410099A (zh) | 2009-04-15 |
RU2008140367A (ru) | 2010-04-20 |
JP2009530325A (ja) | 2009-08-27 |
NZ571354A (en) | 2011-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007110152A2 (de) | Polylactid-nanopartikel | |
DE60311801T2 (de) | Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung | |
EP1817035B1 (de) | Feste formulierungen von flüssigen biologisch wirksamen mitteln | |
EP2819659B1 (de) | Verfahren zur herstellung wirkstoffbeladener nanopartikel | |
G Nava-Arzaluz et al. | Single emulsion-solvent evaporation technique and modifications for the preparation of pharmaceutical polymeric nanoparticles | |
DE60220519T2 (de) | Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe | |
CZ377296A3 (en) | Stabilized and sterilizably filterable nano particles, process of their preparation and pharmaceutical composition containing thereof | |
EP2029119A2 (de) | Funktionalisierte, feste polymernanopartikel für diagnostische und therapeutische anwendungen | |
WO2009074274A1 (de) | Funktionalisierte, feste polymernanopartikel enthaltend epothilone | |
EP2408438A2 (de) | Mit therapeutika und diagnostika beladene kompositmaterialien umfassend polymernanopartikel und polymerfasern | |
CH710313B1 (de) | Anti-Tumor-Medikament mit aktivem Targeting und dessen Herstellungsmethode. | |
CN102099016A (zh) | 载药的聚合物纳米微粒及其制备和使用方法 | |
CN101495148A (zh) | 包括至少一种抗癌药和至少一种聚合物的药物组合物 | |
JP5425890B2 (ja) | 難溶性薬物を含む均一なサイズの高分子ナノ粒子製造方法 | |
CN109381447B (zh) | 一种载虾青素磷脂纳米粒及其制备方法与应用 | |
US10172867B2 (en) | Afobazole nanoparticles formulation for enhanced therapeutics | |
US20210106536A1 (en) | Drug delivery agents for prevention or treatment of pulmonary disease | |
WO2012089220A1 (ru) | Способ получения водорорастворимой лекарственной формы антибиотика из группы рифамицинов и композиция, полученная способом | |
Domb et al. | Lipospheres for controlled delivery of substances | |
US20230270681A1 (en) | Drug delivery agents for prevention or treatment of pulmonary disease | |
EP2355794B1 (de) | Lösungen von lipophilen substanzen, insbesondere arzneistofflösungen | |
WO2019048424A1 (de) | Erfindung betreffend nanopartikel enthaltend taxane zur inhalativen applikation | |
KR20170114245A (ko) | 저분자 메틸셀룰로오스 기반의 비경구 생리활성물질 전달용 조성물 | |
WO2009059989A1 (de) | Einen hydrophoben wirkstoff enthaltende wässrige emulsionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07711937 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007711937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2644411 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 571354 Country of ref document: NZ Ref document number: MX/a/2008/011892 Country of ref document: MX Ref document number: 194209 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008502113 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009500737 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007229738 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12225555 Country of ref document: US Ref document number: 200780010641.3 Country of ref document: CN Ref document number: 8036/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2008140367 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2007229738 Country of ref document: AU Date of ref document: 20070313 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087025603 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0709352 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080922 |